Sharma R, Singh VJ, Chawla PA. Advancements in the use of platinum complexes as anticancer agents. Anticancer Agents Med Chem. 2022;22:821–35.
Article CAS PubMed Google Scholar
Rottenberg S, Disler C, Perego P. The rediscovery of platinum-based cancer therapy. Nature Rev Cancer. 2021;21:37–50.
Johnstone TC, Suntharalingam K, Lippard SJ. The next generation of platinum drugs: targeted Pt (II) agents, nanoparticle delivery and Pt(IV) prodrugs. Chem Rev. 2016;116:3436–86.
Article CAS PubMed PubMed Central Google Scholar
Wheate NJ, Walker S, Craig GE, Oun R. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans. 2010;39:8113–27.
Article CAS PubMed Google Scholar
Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–78.
Article CAS PubMed PubMed Central Google Scholar
DilrubaAffiliated withDepartment of Clinical Pharmacy, Institute of Pharmacy, University of Bonn S, Kalayda GV. Platinum-based drugs: past, present and future. Cancer Chemother Pharmacol. 2016;77:1103–24.
Imran M, Ayub W, Butler IS. Photoactivated platinum-based anticancer drugs. Coord Chem Rev. 2018;376:405–29.
Bai L, Gao C, Liu Q, Yu C, Zhang Z, Cai L, et al. Research progress in modern structure of platinum complexes. Eur J Med Chem. 2017;140:349–82.
Article CAS PubMed Google Scholar
Ahmad S. Kinetic aspects of platinum anticancer agents. Polyhedron. 2017;138:109–24.
Brabec V, Hrabina O, Kasparkova J. Cytotoxic platinum coordination compounds. DNA binding agents. Coord Chem Rev. 2017;351:2–31.
Jamieson ER, Lippard SJ. Structure, recognition and processing of cisplatin-DNA adducts. Chem Rev. 1999;99:2467–98.
Article CAS PubMed Google Scholar
Ahmad S, Isab AA, Ali S. Structural and mechanistic aspects of platinum anticancer agents. Transition Met Chem. 2006;31:1003–16.
Ahmad S. Platinum–DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes. Chem Biodiv. 2010;7:543–66.
Rahiminezhad A, Moghadam ME, Divsalar A, Mesbah AW. How can the cisplatin analogs with different amine act on DNA during cancer treatment theoretically? J Mol Model. 2022;28:2.
Wong D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Disc. 2005;4:307–20.
Jung Y, Lippard SJ. Direct cellular responses to platinum-induced DNA damage. Chem Rev. 2007;107:1387–407.
Article CAS PubMed Google Scholar
Davies MS, Berners-Price SJ, Hambley TW. Slowing of cisplatin aquation in the presence of DNA but not in the presence of phosphate: improved understanding of sequence selectivity and the roles of monoaquated and diaquated species in the binding of cisplatin to DNA. Inorg Chem. 2000;39:5603.
Article CAS PubMed Google Scholar
Kozelka J, Legendre F, Reeder F, Chottard J-C. Kinetic aspects of interactions between DNA and platinum complexes. Coord Chem Rev. 1999;190–192:61.
Wang X, Guo Z. The role of sulfur in platinum anticancer chemotherapy. Anticancer Agents Med Chem. 2007;7:19.
Reedijk J. Why does cisplatin reach guanine-N7 with competing S-donor ligands available in the cell? Chem Rev. 1999;99:2499.
Article CAS PubMed Google Scholar
Berners-Price SJ, Kuchel PW. Reaction of cis-and trans-[PtCl2(NH3)2] with reduced glutathione studied by 1H, 13C, 195Pt and 15N- DEPT NMR. J Inorg Biochem. 1990;38:327.
Article CAS PubMed Google Scholar
Pinato O, Musetti C, Sissi C. Pt-based drugs: the spotlight will be on proteins. Metallomics. 2014;6:380–95.
Article CAS PubMed Google Scholar
Ahmad S, Isab AA, Al-Arfaj AR. Antitumor potential of platinum(II) complexes of selenium donor ligands. Metallomics. 2023;15:mfad020.
Chen S-H, Chang J-Y. New insights into mechanisms of cisplatin resistance: from tumor cell to microenvironment. Int J Mol Sci. 2019;20:4136.
Article PubMed PubMed Central Google Scholar
Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31:1869–83.
Article CAS PubMed Google Scholar
Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007;33:9–23.
Article CAS PubMed Google Scholar
Zhou J, Kang Y, Chen L, Wang H, Liu J, Zeng S, et al. The drug-resistance mechanisms of five platinum-based antitumor agents. Front. Pharmacol. 2020;11:343.
Article CAS PubMed PubMed Central Google Scholar
Amable L. Cisplatin resistance and opportunities for precision medicine. Pharmacol Res. 2016;106:27–36.
Article CAS PubMed Google Scholar
Oun R, Moussa YE, Wheate NJ. The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans. 2018;47:6645–53.
Article CAS PubMed Google Scholar
Piccolini VM, Bottone MG, Bottiroli G, De Pascali SA, Fanizzi FP, Bernocchi G. Platinum drugs and neurotoxicity: effects on intracellular calcium homeostasis. Cell Biol Toxicol. 2013;29:339–53.
Article CAS PubMed Google Scholar
Xin Y, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci. 2007;334:115–24.
Lemma K, Elmroth SKC, Elding LI. Substitution reactions of [Pt(dien)Cl]+, [Pt(dien)(GSMe)]2+, cis-[PtCl2(NH3)2] and cis-[Pt(NH3)2(GSMe)2]2+ (GSMe = S-methylglutathione) with some sulfur-bonding chemoprotective agents. J Chem Soc Dalton Trans. 2002;31:1281–6.
Zhang J-G, Lindup WE. Cisplatin nephrotoxicity: decreases in mitochondrial protein sulphydryl concentration and calcium uptake by mitochondria from rat renal cortical slices. Biochem Pharmacol. 1994;47:1127–35.
Article CAS PubMed Google Scholar
Faraglia G, Fregona D, Sitran S, Giovagnini L, Marzano C, Baccichetti F, et al. Platinum(II) and palladium(II) complexes with dithiocarbamates and amines: synthesis, characterization and cell assay. J Inorg Biochem. 2001;83:31–40.
Article CAS PubMed Google Scholar
Hosseinzadeh S, Moghadam ME, Sheshmani S, Shahvelayati AS. Some new anticancer platinum complexes of dithiocarbamate derivatives against human colorectal and pancreatic cell lines. J Biomol Struc Dynam. 2020;38:2215–28.
留言 (0)